TARGET Protein

• 
  Principal Investigator
  Professor Adam Deane

  View researcher's webpage

Project Details

TARGET  Protein

Background:

It is unknown whether augmenting dietary protein to 1.2-2.0 g/kg/day, as recommended in international clinical practice guidelines, when compared to existing current practice (protein < 1.0 g/kg/day) improves outcomes in intensive care unit (ICU) patients.

The TARGET Protein trial will address this issue.

TARGET Protein is a cluster randomised, cross-sectional, double cross-over, pragmatic clinical trial undertaken in eight ICUs in Australia and New Zealand. Each ICU will be randomised to use one of two trial enteral formulae for three months before crossing over to the other formula, which is then repeated, with enrolment continuing at each ICU for 12 months.

The primary outcome is days free of the index hospital and alive at day 90.

The trial has finished recruiting (3399 patients enrolled) and results will be presented in early 2025.

Funding

National Health and Medical Research Council (NHMRC) Medical Research Future Fund Project Grant ($1,992,218)